https://biotechmorning.com/news/astrazeneca-pinetree-egfr-degrader-deal Biotech Morning en 2026-04-30T14:11:42.543Z AstraZeneca's $25M Bet on a Drug That Destroys What Others Can't Block https://biotechmorning.com/news/astrazeneca-camizestrant-truqap-odac-meeting-fda-concerns Biotech Morning en 2026-04-30T14:11:02.608Z AstraZeneca's Two Biggest Cancer Bets Just Hit the Same Wall https://biotechmorning.com/news/teva-700m-emalex-tourette-syndrome-bet Biotech Morning en 2026-04-30T14:10:17.561Z Teva's $700M Bet on a Drug That Hasn't Been Updated in 50 Years https://biotechmorning.com/news/avalyn-pharma-300m-ipo-inhaled-pulmonary-fibrosis Biotech Morning en 2026-04-30T14:09:39.194Z The $300M Bet That Breathing Easier Starts in the Lungs https://biotechmorning.com/news/2-billion-bet-preclinical-trispecific-antibody Biotech Morning en 2026-04-30T14:08:55.107Z A $2 Billion Bet on a Drug That Hasn't Touched a Human Yet https://biotechmorning.com/news/fda-clinical-hold-newron-schizophrenia-trial Biotech Morning en 2026-04-30T14:08:12.617Z A Patient Died in a Schizophrenia Trial. Now the FDA Wants Answers. https://biotechmorning.com/news/gsk-alector-alzheimers-second-failure Biotech Morning en 2026-04-30T14:07:32.867Z GSK Bet $700M on a Brain Theory. It Just Lost Twice. https://biotechmorning.com/news/chiesi-kalvista-oral-hae-acquisition Biotech Morning en 2026-04-30T14:06:50.916Z The $1.9B Bet That Needles Are Going Extinct in One Corner of Medicine https://biotechmorning.com/news/flap-inhibitor-asthma-failure-astrazeneca Biotech Morning en 2026-04-29T14:13:02.522Z The Asthma Drug Class That Just Can't Catch a Break https://biotechmorning.com/news/teva-emalex-tourette-syndrome-deal Biotech Morning en 2026-04-29T14:12:21.980Z Teva Just Dropped $700M on a Drug for a Disease With Limited Treatment Options https://biotechmorning.com/news/fda-real-time-clinical-trial-review Biotech Morning en 2026-04-29T14:11:38.909Z The FDA Wants to Watch Your Clinical Trial Live https://biotechmorning.com/news/gsk-oncology-gamble-future Biotech Morning en 2026-04-29T14:10:59.733Z GSK's Oncology Gamble Could Rewrite Its Entire Future https://biotechmorning.com/news/coultreon-galapagos-drug-125m-series-a Biotech Morning en 2026-04-29T14:10:23.844Z Galapagos Ditched This Drug. Now It Just Raised $125 Million. https://biotechmorning.com/news/incyte-opzelura-vitiligo-rinvoq-competition Biotech Morning en 2026-04-29T14:09:42.929Z Incyte's Skin Cream Just Won Big. So Why Is Wall Street Nervous? https://biotechmorning.com/news/erasca-home-run-stock-drops Biotech Morning en 2026-04-29T14:08:52.547Z Erasca Hit a Home Run. The Stock Fell 47%. https://biotechmorning.com/news/astrazeneca-fda-concerns-camizestrant-truqap Biotech Morning en 2026-04-29T14:08:05.823Z AstraZeneca's Two Biggest Cancer Bets Just Hit a Wall